Nu Holdings Ltd. (NU) Stock News

CLINUVEL Pharmaceuticals announced its tenth consecutive annual profit for FY2026 with revenues of $94.0 million and net profit after tax of $33.9 million. The company declared a $0.05 per share dividend and increased cash reserves to $252.1 million, providing financial independence to pursue expansion strategy, particularly in North America. Despite marginal revenue decline due to U.S. market competition and inventory practice changes, the company maintained disciplined expense control and achieved record SCENESSE treatment volumes.

VINCI, a French public limited company, disclosed its capital structure as of 31 July 2026, with 587,033,654 total shares and €1,467,584,135.00 in share capital. The company announced the implementation of its share buyback programme through a share purchase agreement signed with an investment partner.

Grabar Law Office has initiated multiple shareholder investigations into alleged securities fraud and fiduciary duty breaches at EquipmentShare.com, Insulet Corporation, New Era Energy & Digital, and Planet Fitness. The investigations allege undisclosed related-party transactions, defective manufacturing controls, misleading statements about business progress, and false marketing claims that caused shareholders to purchase securities at artificially inflated prices.

Ferrari N.V. announced Q2 2026 net revenues of €1,938 million (up 8% YoY), operating profit of €605 million with a 31.2% margin, and net profit of €463 million. The company raised its 2026 guidance citing stronger-than-expected personalizations and lower currency headwinds. The order book covers deliveries through 2027, with new model launches including the Ferrari Luce and 12Cilindri Manuale contributing to the company's most complete product lineup in history.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 VERITAC-2 trial, vepdegestrant demonstrated a 43% reduction in disease progression or death risk compared to fulvestrant in patients with ESR1 mutations.

Grabar Law Office announced investigations into multiple publicly traded companies on behalf of shareholders, alleging breaches of fiduciary duties and securities law violations. The investigations cover Erasca (misleading statements about ERAS-0015 drug candidate and patent infringement), Insulet (defective manufacturing controls leading to product recalls), New Era Energy & Digital (overstated project progress and fraudulent oil-and-gas schemes), Power Solutions International (overstated sales demand and understated manufacturing costs), Hub Group, Planet Fitness, Primoris Services, EquipmentShare.com, GPGI, Photronics, and Via Transportation. Shareholders who meet specific holding criteria may seek damages and corporate governance reforms at no cost.

CLINUVEL Pharmaceuticals announced a strategic reorganisation effective January 1, 2027, relocating its corporate headquarters from Australia to the United States and reducing its global workforce by 10-20%. The restructuring aims to strengthen U.S. regulatory engagement, focus operations on the U.S. pharmaceutical market, and unlock deeper capital pools from U.S. investors who prefer U.S.-listed companies. The move is driven by the company's recognition that U.S.-listed specialty pharma companies command higher valuation multiples and that over 66% of its shareholder base is already foreign investors.

ARCpoint Inc. (TSXV: ARC), a healthcare technology company, announced it will miss its July 29, 2026 filing deadline for annual financial statements due to lack of available funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and expects to file by September 29, 2026. During the MCTO period, insiders will be restricted from trading shares, though public trading will continue.

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) in London. The company highlighted advances in blood-based biomarker profiling, particularly the eMTBR-Tau and BD-pTau217 tests, which can be measured simultaneously with 220+ CNS-related proteins in a single workflow. This represents a four-fold increase from the previous AAIC conference, demonstrating growing adoption of the technology in Alzheimer's research.

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) 2026 in London. The company introduced its first multiplex blood immunoassay for eMTBR-Tau, a key Alzheimer's biomarker, which can be detected alongside over 220 disease-related proteins in a single workflow. The data demonstrates that combined detection of BD-pTau217 and eMTBR-Tau improves disease stratification compared to single biomarker testing.

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions to determine if shareholders are receiving fair deals. The investigations cover LCI Industries' sale to Patrick Industries, Nuvalent's acquisition by GSK, Dana Incorporated's merger with Eaton Corporation, and Taylor Morrison's sale to Berkshire Hathaway. The firm is examining potential securities law violations and breaches of fiduciary duties, particularly regarding insider benefits and terms that may limit competing offers.

LA21-CDC received grant support from Truist Foundation to expand its Small Business Sustainability Initiative, which provides Philadelphia entrepreneurs with coaching, business systems training, capital readiness support, and AI-powered business tools to strengthen operations and build long-term sustainability.

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Arcosa (CRH acquisition for $150/share), Fathom Holdings (Bed Bath & Beyond acquisition), Nuvalent (GSK acquisition for $124/share), and Dana Incorporated (Eaton Corporation acquisition).

InnSuites Hospitality Trust (IHT) reported Fiscal Q1 2027 net income of $74,702, a $35,672 improvement year-over-year, with record hotel revenue of $2.2 million and combined occupancy reaching 85.37%. The company continues exploring diversification opportunities including a potential reverse merger, IBC Hotels independent hotel services, and investments in UniGen Power's clean energy technology.

Monteverde & Associates PC is investigating four merger and acquisition transactions on behalf of shareholders. Pacific Financial Corporation is merging with Banner Corporation (0.2633 shares per share), Nuvalent Inc. is being acquired by GSK plc ($124.00 per share), Cross Country Healthcare is being sold to KL Criss Cross Intermediate LLC ($13.25 per share), and Bio Green Med Solution is merging with Future NRG Sdn. Bhd. Shareholders are encouraged to contact the firm regarding potential concerns with these transactions.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Delivered strong Q1 2026 comparable store sales growth 1 of 22.6% and total revenue growth of 37.0% Achieved a four-year high gross margin 1 of 67.4 %, an increase of 530 bps Expanded adjusted EBITDA margin 1 to 36.8 %, underscoring our luxury-inspired business model Continued successful expansion with new stores outperforming expectations Raised adjusted EBITDA margin guidance for Fiscal 2026 to 38.25%–39.50 % MONTRÉAL , June 16, 2026 /CNW/ - Groupe Dynamite Inc. ("Groupe Dynamite" or the "Company") (TSX: GRGD ) today reported its financial results for the fiscal year 2026's first quarter ended May 2, 2026. "Our first quarter results demonstrate the strength of our operating model and our ability to deliver profitable growth. Comparable store sales increased 22.6%, gross margin reached a four-year high, and adjusted EBITDA margin expanded to 36.8% of revenue, positioning ourselves alongside the world's most profitable fashion houses. We continue to strive to remain a highly productive specialty retailer with strong brands, exceptional unit economics, disciplined inventory management, attractive returns on capital, and a growth engine we have built over decades that continues to scale profitably," said Andrew Lutfy, Chief Executive Officer and Chair of the Board. "Q1 was a strong start to fiscal 2026. Across both GARAGE and DYNAMITE, customers responded positively to our assortments, marketing campaigns and the consistency of the experience we deliver across channels. Our real estate strategy continues to be a significant driver of growth, customer acquisition and profitability. By opening new locations in premium centers, optimizing our fleet and delivering a compelling in-store experience, we continue to drive significant productivity improvements across our store network. Most importantly, we continue to see strong customer engagement across both brands, reflected

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

SINGAPORE , June 8, 2026 /PRNewswire/ -- VinFast Auto Ltd. announced its unaudited financial results for the first quarter ended March 31, 2026. In the first quarter of 2026, VinFast ("the Company") delivered 58,577 electric vehicles, representing an increase of 61% from the same period last year. International markets accounted for approximately 8% of total deliveries during the quarter. In Vietnam, VinFast's EV deliveries in the first quarter of 2026 increased by 53% year over year. The Company maintained its position as the number one OEM in the domestic automotive market since September 2024. Southeast Asia and India continue to be key growth markets for VinFast. At the end of the first quarter of 2026, VinFast ranked #1 BEV brand in the Philippines, #4 in India and #8 in Indonesia. The Company also delivered 143,136 units of e-scooters and e-bikes in the first quarter, representing an increase of 219% from the first quarter of 2025. In March alone, VinFast received more than 135,000 e-scooter orders and shipped over 93,000 e-scooters to dealers in Vietnam. VinFast currently holds the leading position in Vietnam's electric motorcycle market and, in March, expanded its share of the overall motorcycle market (including both ... Full story available on Benzinga.com

Grabar Law Office has filed multiple federal securities fraud class action complaints against Badger Meter, Calix, New Era Energy & Digital, and Power Solutions International, alleging that officers and directors made false or misleading statements about financial performance, business operations, and growth prospects. Shareholders who purchased shares during specified periods may seek corporate reforms and compensation.

Excluding significant items, quarterly earnings per common share of $0.48 (1) Increased quarterly dividend 17.6 % to $ 0.10 per common share TORONTO , June 3, 2026 /CNW/ - Canaccord Genuity Group Inc. (Canaccord Genuity Group, the Company) (TSX: CF ) today announced its financial results for the fourth quarter and fiscal year ended March 31, 2026. "We delivered record revenue in fiscal 2026 and significantly improved profitability, reflecting stronger operating leverage and disciplined execution across the platform," said Dan Daviau, Chairman & CEO of Canaccord Genuity Group Inc. "Capital markets growth was led by higher investment banking and advisory activity, while wealth management continued to scale, supported by market appreciation, targeted investment and positive inflows. Our improved earnings profile and continued focus on disciplined capital allocation supported our decision to increase the dividend, while preserving the flexibility to invest in the areas of the business where we see the strongest opportunities to create long-term shareholder value." Fourth quarter and fiscal 2026 highlights (adjusted): (All dollar amounts are stated in thousands of Canadian dollars and on an adjusted basis excluding significant items ( 1 ) unless otherwise indicated) Fourth quarter revenue of $612.7 million, an increase of 33.2% over the same period in the prior fiscal year and the third highest quarterly revenue on record Fiscal 2026 revenue of $2.2 billion increased by 24.9% year over year Global wealth management operations earned record quarterly revenue of $306.7 million and record revenue of $1.1 billion for fiscal 2026, year-over-year improvements of 28.4% and 24.2%. Fourth quarter growth in the Australian wealth management operations reflects contributions from the acquisition of Wilsons Advisory Global capital markets revenue for the fourth quarter of $291.6 mi

All amounts are unaudited and in Canadian dollars and are based on financial statements prepared in compliance with International Accounting Standard 34 Interim Financial Reporting, unless otherwise noted. Our second quarter 2026 ("Q2 2026") unaudited Interim Consolidated Financial Statements for the period ended April 30, 2026 and Management's Discussion and Analysis ("MD&A"), are available online at www.versabank.com/investor-relations , SEDAR at www.sedarplus.ca and EDGAR at www.sec.gov/edgar . Supplementary Financial Information will also be available on our website at www.versabank.com/investor-relations . LONDON, ON , June 3, 2026 /CNW/ - VersaBank (or the "Bank") (TSX: VBNK (NASDAQ: VBNK ), a North American leader in business-to-business digital banking, as well as technology solutions for cybersecurity, today reported its results for the second quarter ended April 30, 2026. All figures are in Canadian dollars unless otherwise stated. NOTE REGARDING SECOND QUARTER FISCAL 2026 FINANCIAL RESULTS VersaBank's financial results for the second quarter of fiscal 2026 reflect non-core non-interest expenses in the amount of $6.7 million. The non-core non-interest expenses included $4.5 million related to the project costs associated with the Reorganization (see Reorganization note below). Subsequent to the end of the second quarter, the Bank publicly filed a Form S-4 registration statement (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Reorganization. The Reorganization is intended to enhance shareholder value, mitigate risk and reduce corporate costs over the long term. The Bank expects that the anticipated benefits of the Reorganization will exceed the associated investment however, these expected benefits are subject to various assumptions and uncertainties. As of the end of the second quarter of

Q1 Revenue Up 44% YoY; Same-Store Sales Up 29%; Adjusted EBITDA Turns Positive as Company Advances National Expansion Strategy EDMONTON, AB , June 1, 2026 /CNW/ - Dr. Phone Fix Canada Corporation (TSXV: DPF) ("Dr. Phone Fix" or the "Company"), one of Canada's fastest-growing and award-winning consumer electronics repair and resale platforms, today reported financial results for the three months ended March 31, 2026, and provided an update on recent corporate developments. The Company operates a network of 44 corporately owned stores across five Canadian provinces. Financial Results Summary (CAD) (all dollar amounts in 000's) Three Months Ended Mar 31, 2026 Three Months Ended Mar 31, 2025 Variance (%) Revenue 3,162 2,196 +44 % Gross Profit 1,621 1,210 +34 % Gross Margin 51.3 % 55.1 % -3.8 pp Operating Expenses (SG&A) 2,476 1,754 +41 % Adjusted EBITDA(1) 88 (13) n/m Cash 291 1,558 -81 % (1) See Non-GAAP Financial Measure towards the end of this document. "Q1 reflected continued progress in the execution of our strategy with revenue increasing 44% year-over-year and comparable-store sales increasing 29%, even in what is typically our seasonally weakest quarter," said Piyush Sawhney, Founder and Chief Executive Officer of Dr. Phone Fix. "We also delivered positive Adjusted EBITDA, generated positive operating cash flow, and continued to improve execution across our national network while integrating recently acquired locations and advancing our OEM, insurance, supplier, repair and certified pre-owned device programs." Mr. Sawhney continued, "We have spent the past year building the foundation for a national, carrier-neutral device lifecycle platform. Today, we have 44 corporately owned locations across five provinces, a growing pipeline of acquisition and greenfield opportunities, and a strategy focused on disciplined expansion and stronger unit-level economics throug

Rosen Law Firm reminds investors in New Era Energy & Digital, Inc. (NUAI) who purchased securities between November 6, 2024 and December 29, 2025 of the June 1, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made false statements about its Texas Critical Data Centers project and was involved in a fraudulent scheme regarding oil and gas wells in New Mexico, resulting in misleading financial results.

A class action lawsuit has been filed against New Era Energy & Digital, Inc. (NASDAQ: NUAI) for allegedly making false statements about its Texas Critical Data Centers project and engaging in a fraudulent scheme involving oil and gas wells in New Mexico. Investors who purchased securities between November 6, 2024 and December 29, 2025 can seek lead plaintiff status by June 1, 2026.

A class action lawsuit has been filed against New Era Energy & Digital, Inc. (NUAI) for alleged securities fraud. The company is accused of overstating progress on regulatory permits for its data center project and participating in a fraudulent scheme involving oil and gas wells in New Mexico, including transferring wells among related entities and placing liability-bearing companies into bankruptcy to avoid environmental cleanup costs. The stock fell significantly following reports from Fuzzy Panda Research and the New Mexico Attorney General's lawsuit.

Rosen Law Firm is notifying investors in New Era Energy & Digital, Inc. (NUAI) of a securities class action lawsuit with a June 1, 2026 lead plaintiff deadline. The lawsuit alleges that New Era Energy made false statements about its Texas Critical Data Centers project progress and was involved in a fraudulent scheme regarding oil and gas wells in New Mexico, resulting in misleading financial results. Investors with losses exceeding $100K are encouraged to seek counsel.

UMH Properties, Inc. announced the reelection of its four directors at the 2026 annual shareholder meeting. The company highlighted strong performance with a 16.4% three-year total shareholder return and 159.5% ten-year return, positioning it among top-performing REITs. UMH also received multiple industry awards including Community Operator of the Year for the fifth time from the Manufactured Housing Institute.

Pomerantz LLP has filed a class action lawsuit against New Era Energy & Digital, Inc. (NUAI) for alleged securities fraud and unlawful business practices. The lawsuit follows damaging reports from Fuzzy Panda Research and Hunterbrook Media alleging that CEO Everett Willard Gray II has a history of mismanaging oil & gas companies, acquiring bankrupt wells, and making false statements to regulators. The stock fell 6.9% on December 12, 2025, and 41.01% on December 29, 2025, following the negative reports.

Olema Oncology announced a clinical trial collaboration with Bayer to evaluate OP-3136, a KAT6 inhibitor, in combination with darolutamide in approximately 36 patients with metastatic castration-resistant prostate cancer. The Phase 1b/2 study is expected to initiate in H2 2026 and represents the first clinical collaboration for OP-3136. Olema will lead the study while maintaining full global commercial rights to OP-3136, with clinical data and inventions jointly owned.